Recombinant CD95-Fc (APG101) prevents graft-versus-host disease in mice without disabling antitumor cytotoxicity and T-cell functions

Blood

Volumn 121, Issue 3, 2013, Pages 556-565

  Hartmann, Natalie ^a   Messmann, Joanna J ^a   Leithäuser, Frank ^b   Weiswange, Maxi ^a   Kluge, Michael ^c   Fricke, Harald ^c   Debatin, Klaus Michael ^a   Strauss, Gudrun ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c APOGENIX GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; APG 101; BCR ABL PROTEIN; FAS ANTIGEN; FAS LIGAND; FC RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN G1 ANTIBODY; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTITUMOR CYTOTOXICITY; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; BONE MARROW TRANSPLANTATION; CYTOTOXICITY; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; IN VITRO STUDY; MASTOCYTOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; T LYMPHOCYTE;

EID: 84872581224     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-04-423392     Document Type: Article

References (48)

1. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol. 2007;25:139-170. (Pubitemid 46697905)
2. Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood. 2001;98(12):3192-3204.
3. Ferrara JL, Levine JE, Reddy P, Holler E. Graftversus- host disease. Lancet. 2009;373(9674): 1550-1561.
4. Socie G, Blazar BR. Acute graft-versus-host disease: from the bench to the bedside. Blood. 2009;114(20):4327-4336.
5. Zheng H, Matte-Martone C, Li H, et al. Effector memory CD4+ T cells mediate graft-versusleukemia without inducing graft-versus-host disease. Blood. 2008;111(4):2476-2484. (Pubitemid 351451463)
6. Dutt S, Baker J, Kohrt HE, et al. CD8+CD44(hi) but not CD4+CD44(hi) memory T cells mediate potent graft antilymphoma activity without GVHD. Blood. 2011;117(11):3230-3239.
7. Hartmann N, Leithauser F, Albers C, et al. In vitroestablished alloantigen-specific CD8+ CTLs mediate graft-versus-tumor activity in the absence of graft-versus-host disease. Leukemia. 2011;25(5): 848-855.
8. Sackstein R. A revision of Billingham's tenets: the central role of lymphocyte migration in acute graft-versus-host disease. Biol Blood Marrow Transplant. 2006;12(1 Suppl 1):2-8. (Pubitemid 43034112)
9. Coghill JM, Sarantopoulos S, Moran TP, Murphy WJ, Blazar BR, Serody JS. Effector CD4+T cells, the cytokines they generate, and GVHD: something old and something new. Blood. 2011;117(12):3268-3276.
10. Hattori K, Hirano T, Miyajima H, et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood. 1998;91(11):4051-4055. (Pubitemid 28261965)
11. Tsukada N, Kobata T, Aizawa Y, Yagita H, Okumura K. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Blood. 1999;93(8):2738-2747. (Pubitemid 29181207)
12. Baker MB, Altman NH, Podack ER, Levy RB. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med. 1996;183(6): 2645-2656. (Pubitemid 26192373)
13. Schmaltz C, Alpdogan O, Horndasch KJ, et al. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graftversus- host disease and graft-versus-leukemia effect. Blood. 2001;97(9):2886-2895.
14. Schmaltz C, Alpdogan O, Kappel BJ, et al. T cells require TRAIL for optimal graft-versus-tumor activity. Nat Med. 2002;8(12):1433-1437. (Pubitemid 36019429)
15. Na IK, Lu SX, Yim NL, et al. The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease. J Clin Invest. 2010;120(1):343-356.
16. Tuettenberg J, Seiz M, Debatin KM, et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients. Int Immunopharmacol. 2012;13(1):93-100.
17. Chen L, Park SM, Tumanov AV, et al. CD95 promotes tumour growth. Nature. 2010;465(7297): 492-496.
18. Peter ME, Budd RC, Desbarats J, et al. The CD95 receptor: apoptosis revisited. Cell. 2007; 129(3):447-450. (Pubitemid 46660984)
19. WickW,Weller M,Weiler M, Batchelor T, YungAW, Platten M. Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro Oncol. 2011; 13(6):566-579.
20. Sun M, Fink PJ. A new class of reverse signaling costimulators belongs to the TNF family. J Immunol. 2007;179(7):4307-4312.
21. Sun M, Lee S, Karray S, Levi-Strauss M, Ames KT, Fink PJ. Cutting edge: two distinct motifs within the Fas ligand tail regulate Fas ligand-mediated costimulation. J Immunol. 2007;179(9):5639-5643.
22. Luckerath K, Kirkin V, Melzer IM, et al. Immune modulation by Fas ligand reverse signaling: lymphocyte proliferation is attenuated by the intracellular Fas ligand domain. Blood. 2011;117(2):519-529.
23. Cooke KR, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood. 1996; 88(8):3230-3239. (Pubitemid 26357409)
24. Miething C, Grundler R, Mugler C, et al. Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment. Proc Natl Acad Sci U S A. 2007;104(11):4594-4599. (Pubitemid 47186270)
25. Kaplan DH, Anderson BE, McNiff JM, Jain D, Shlomchik MJ, Shlomchik WD. Target antigens determine graft-versus-host disease phenotype. J Immunol. 2004;173(9):5467-5475. (Pubitemid 39392131)
26. Strauss G, Knape I, Melzner I, Debatin KM. Constitutive caspase activation and impaired deathinducing signaling complex formation in CD95- resistant, long-term activated, antigen-specific T cells. J Immunol. 2003;171(3):1172-1182. (Pubitemid 36900045)
27. Graubert TA, DiPersio JF, Russell JH, Ley TJ. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J Clin Invest. 1997; 100(4):904-911. (Pubitemid 27371709)
28. Kataoka T, Togashi K, Takayama H, Takaku K, Nagai K. Inactivation and proteolytic degradation of perforin within lytic granules upon neutralization of acidic pH. Immunology. 1997;91(3):493-500. (Pubitemid 27304288)
29. Miwa K, Hashimoto H, Yatomi T, Nakamura N, Nagata S, Suda T. Therapeutic effect of an anti- Fas ligand mAb on lethal graft-versus-host disease. Int Immunol. 1999;11(6):925-931. (Pubitemid 29276604)
30. Kuwahara H, Tani Y, Ogawa Y, Takaichi Y, Shiraishi A, Ohtsuki M. Therapeutic effect of novel anti-human Fas antibody HFE7a on graftversus- host disease model. Clin Immunol. 2001; 99(3):340-346.
31. Sprent J, Schaefer M, Gao EK, Korngold R. Role of T-cell subsets in lethal graft-versus-host disease (GVHD) directed to class I versus class II H-2 differences. I. L3T4+ cells can either augment or retard GVHD elicited by Lyt-2+ cells in class I different hosts. J Exp Med. 1988;167(2): 556-569. (Pubitemid 18073654)
32. Teshima T, Hill GR, Pan L, et al. IL-11 separates graft-versus-leukemia effects from graft-versushost disease after bone marrow transplantation. J Clin Invest. 1999;104(3):317-325.
33. Kim J, Kim HJ, Park K, et al. Costimulatory molecule-targeted immunotherapy of cutaneous graft-versus-host disease. Blood. 2007;110(2): 776-782. (Pubitemid 47105417)
34. Graubert TA, Russell JH, Ley TJ. The role of granzyme B in murine models of acute graftversus- host disease and graft rejection. Blood. 1996;87(4):1232-1237. (Pubitemid 26060539)
35. Min CK, Maeda Y, Lowler K, et al. Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation. Blood. 2004;104(10):3393-3399. (Pubitemid 39507164)
36. Jiang Z, Podack E, Levy RB. Major histocompatibility complex-mismatched allogeneic bone marrow transplantation using perforin and/or Fas ligand double-defective CD4(+) donor T cells: involvement of cytotoxic function by donor lymphocytes prior to graft-versus-host disease pathogenesis. Blood. 2001;98(2):390-397.
37. Marks L, Altman NH, Podack ER, Levy RB. Donor T cells lacking Fas ligand and perforin retain the capacity to induce severe GvHD in minor histocompatibility antigen mismatched bone-marrow transplantation recipients. Transplantation. 2004; 77(6):804-812. (Pubitemid 38436815)
38. Ramirez-Montagut T, Chow A, Kochman AA, et al. IFN-gamma and Fas ligand are required for graftversus- tumor activity against renal cell carcinoma in the absence of lethal graft-versus-host disease. J Immunol. 2007;179(3):1669-1680.
39. Janssen EM, Lemmens EE, Gour N, et al. Distinct roles of cytolytic effector molecules for antigen-restricted killing by CTL in vivo. Immunol Cell Biol. 2010;88(7):761-765.
40. Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity. 2009;30(2):180-192.
41. Strauss G, Lindquist JA, Arhel N, et al. CD95 costimulation blocks activation of naive T cells by inhibiting T-cell receptor signaling. J Exp Med. 2009;206(6):1379-1393.
42. Weiss EM, Schmidt A, Vobis D, et al. Foxp3- mediated suppression of CD95L expression confers resistance to activation-induced cell death in regulatory T cells. J Immunol. 2011;187(4):1684-1691.
43. Via CS, Nguyen P, Shustov A, Drappa J, Elkon KB. Amajor role for the Fas pathway in acute graftversus- host disease. J Immunol. 1996;157(12):5387-5393. (Pubitemid 126448957)
44. Iwasaki T, Hamano T, Saheki K, et al. Graftversus- host-disease- associated donor cell engraftment in an F1 hybrid model is dependent upon the Fas pathway. Immunology. 2000;99(1): 94-100. (Pubitemid 30062943)
45. Kanda Y, Tanaka Y, Shirakawa K, et al. Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease. Bone Marrow Transplant. 1998;22(8):751-754. (Pubitemid 28488317)
46. Takada S, Hatsumi N, Saito T, et al. Two cases of chronic graft-versus-host disease with elevated levels of soluble Fas ligand in serum. Am J Hematol. 2000;64(2):133-136. (Pubitemid 30324473)
47. Jaksch M, Uzunel M, Martinez Cangana G, Remberger M, Mattsson J. Increased levels of immune transcript in patients with acute GVHD after allogeneic stem cell transplantation. Bone Marrow Transplant. 2003;31(3):183-190. (Pubitemid 36305572)
48. Jaksch M, Remberger M, Mattsson J. Increased immune transcript levels are correlated with acute graft-versus-host disease and cytomegalovirus response after allogeneic stem cell transplantation. Transplantation. 2004;77(2):195-200. (Pubitemid 38155745)